HUE036103T2 - Polipurin szakaszon módosított retrovirális vektorok - Google Patents
Polipurin szakaszon módosított retrovirális vektorokInfo
- Publication number
- HUE036103T2 HUE036103T2 HUE08859393A HUE08859393A HUE036103T2 HU E036103 T2 HUE036103 T2 HU E036103T2 HU E08859393 A HUE08859393 A HU E08859393A HU E08859393 A HUE08859393 A HU E08859393A HU E036103 T2 HUE036103 T2 HU E036103T2
- Authority
- HU
- Hungary
- Prior art keywords
- retroviral vectors
- polypurine tract
- modified retroviral
- modified
- polypurine
- Prior art date
Links
- 230000001177 retroviral effect Effects 0.000 title 1
- 239000013598 vector Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/24—Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polyurethanes Or Polyureas (AREA)
- Artificial Filaments (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US711807P | 2007-12-11 | 2007-12-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE036103T2 true HUE036103T2 (hu) | 2018-06-28 |
Family
ID=40756119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE08859393A HUE036103T2 (hu) | 2007-12-11 | 2008-12-11 | Polipurin szakaszon módosított retrovirális vektorok |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9796987B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2222861B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP5749014B2 (cg-RX-API-DMAC7.html) |
| CY (1) | CY1119905T1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK2222861T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2664988T3 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20180184T1 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE036103T2 (cg-RX-API-DMAC7.html) |
| LT (1) | LT2222861T (cg-RX-API-DMAC7.html) |
| NO (1) | NO2222861T3 (cg-RX-API-DMAC7.html) |
| PL (1) | PL2222861T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2222861T (cg-RX-API-DMAC7.html) |
| RS (1) | RS56844B1 (cg-RX-API-DMAC7.html) |
| SI (1) | SI2222861T1 (cg-RX-API-DMAC7.html) |
| TR (1) | TR201802323T4 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009076524A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006252406B2 (en) | 2005-06-01 | 2012-05-17 | California Institute Of Technology | Method of targeted gene delivery using viral vectors |
| PL2048955T3 (pl) | 2006-07-21 | 2013-11-29 | California Inst Of Techn | Nakierowane dostarczanie genu dla szczepienia komórek dendrytycznych |
| WO2009076524A2 (en) | 2007-12-11 | 2009-06-18 | The University Of North Carolina At Chapel Hill | Polypurine tract modified retroviral vectors |
| SG177744A1 (en) * | 2009-07-24 | 2012-02-28 | Immune Design Corp | Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein |
| EP2675473A1 (en) | 2011-02-15 | 2013-12-25 | Immune Design Corp. | Methods for enhancing immunogen specific immune responses by vectored vaccines |
| WO2012141984A1 (en) | 2011-04-08 | 2012-10-18 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
| US9713635B2 (en) | 2012-03-30 | 2017-07-25 | Immune Design Corp. | Materials and methods for producing improved lentiviral vector particles |
| US8323662B1 (en) | 2012-03-30 | 2012-12-04 | Immune Design Corp. | Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein |
| NZ700340A (en) | 2012-03-30 | 2017-02-24 | Immune Design Corp | Lentiviral vector particles having improved transduction efficiency for cells expressing dc- sign |
| CN107540730B (zh) | 2012-05-16 | 2021-07-16 | 免疫设计公司 | 用于hsv-2的疫苗 |
| EP3542816A1 (en) | 2014-02-14 | 2019-09-25 | Immune Design Corp. | Immunotherapy of cancer through combination of local and systemic immune stimulation |
| WO2016011083A1 (en) | 2014-07-15 | 2016-01-21 | Immune Design Corp. | Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector |
| KR101607282B1 (ko) | 2014-12-18 | 2016-03-29 | 충남대학교산학협력단 | 유리형 산화환원조절단백-1 및 이를 함유하는 항염증 약학조성물 |
| WO2016118780A1 (en) * | 2015-01-21 | 2016-07-28 | Fred Hutchinson Cancer Research Center | Point-of-care and/or portable platform for gene therapy |
| WO2017066570A1 (en) * | 2015-10-15 | 2017-04-20 | The University Of North Carolina At Chapel Hill | Methods and compositions for integration-defective lentiviral vectors |
| WO2017068419A2 (en) | 2015-10-22 | 2017-04-27 | Juno Therapeutics Gmbh | Methods, kits, agents and apparatuses for transduction |
| EP3738973A1 (en) | 2015-11-09 | 2020-11-18 | Immune Design Corp. | Compositions comprising lentiviral vectors expressing il-12 and methods of use thereof |
| US11135283B2 (en) | 2015-11-09 | 2021-10-05 | Immune Design Corp. | Retroviral vector for the administration and expression of replicon RNA expressing heterologous nucleic acids |
| EA201891717A1 (ru) | 2016-02-23 | 2019-02-28 | Иммьюн Дизайн Корп. | Препараты мультигеномных ретровирусных векторов и способы и системы для их получения и применения |
| KR20230051602A (ko) | 2016-04-15 | 2023-04-18 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Icos 리간드 변이체 면역조절 단백질 및 그의 용도 |
| KR20190006495A (ko) | 2016-04-15 | 2019-01-18 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Cd80 변이체 면역조절 단백질 및 그의 용도 |
| WO2018022945A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd112 variant immunomodulatory proteins and uses thereof |
| US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
| EP3491013A1 (en) | 2016-07-28 | 2019-06-05 | Alpine Immune Sciences, Inc. | Cd155 variant immunomodulatory proteins and uses thereof |
| ES2926513T3 (es) | 2016-07-29 | 2022-10-26 | Juno Therapeutics Inc | Métodos para evaluar la presencia o ausencia de virus competente en replicación |
| MX2019006438A (es) | 2016-12-05 | 2019-11-28 | Juno Therapeutics Inc | Produccion de celulas modificadas para terapia de celulas adoptivas. |
| EP3596115A1 (en) | 2017-03-16 | 2020-01-22 | Alpine Immune Sciences, Inc. | Pd-l2 variant immunomodulatory proteins and uses thereof |
| US20230220039A1 (en) | 2017-03-16 | 2023-07-13 | Alpine Immune Sciences, Inc. | Pd-l1 variant immunomodulatory proteins and uses thereof |
| WO2018170026A2 (en) | 2017-03-16 | 2018-09-20 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
| KR20200064060A (ko) | 2017-07-29 | 2020-06-05 | 주노 쎄러퓨티크스 인코퍼레이티드 | 재조합 수용체를 발현하는 세포 증폭용 시약 |
| AU2018313950A1 (en) | 2017-08-09 | 2020-02-13 | Juno Therapeutics, Inc. | Methods for producing genetically engineered cell compositions and related compositions |
| KR102813968B1 (ko) | 2017-10-10 | 2025-05-29 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Ctla-4 변이체 면역조절 단백질 및 이의 용도 |
| SG11202003078VA (en) | 2017-10-18 | 2020-05-28 | Alpine Immune Sciences Inc | Variant icos ligand immunomodulatory proteins and related compositions and methods |
| US20210254000A1 (en) | 2017-11-01 | 2021-08-19 | Juno Therapeutics, Inc. | Process for producing a t cell composition |
| DK3704230T3 (da) | 2017-11-01 | 2025-01-02 | Juno Therapeutics Inc | Fremgangsmåde til generering af terapeutiske sammensætninger af modificerede celler |
| SG11202005228YA (en) | 2017-12-08 | 2020-07-29 | Juno Therapeutics Inc | Serum-free media formulation for culturing cells and methods of use thereof |
| BR112020013236A2 (pt) | 2018-01-03 | 2020-12-01 | Alpine Immune Sciences, Inc. | proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso |
| WO2019152747A1 (en) | 2018-01-31 | 2019-08-08 | Juno Therapeutics, Inc. | Methods and reagents for assessing the presence or absence of replication competent virus |
| WO2019241758A1 (en) | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
| WO2020061376A2 (en) | 2018-09-19 | 2020-03-26 | Alpine Immune Sciences, Inc. | Methods and uses of variant cd80 fusion proteins and related constructs |
| SG11202104188VA (en) | 2018-11-01 | 2021-05-28 | Juno Therapeutics Inc | Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen |
| BR112021009420A2 (pt) | 2018-11-16 | 2021-11-23 | Juno Therapeutics Inc | Métodos de dosagem de células t manipuladas para o tratamento de malignidades de células b |
| EP3886875B1 (en) | 2018-11-30 | 2024-05-08 | Juno Therapeutics, Inc. | Methods for treatment using adoptive cell therapy |
| AU2019389151B2 (en) | 2018-11-30 | 2025-07-24 | Alpine Immune Sciences, Inc. | CD86 variant immunomodulatory proteins and uses thereof |
| MX2021006244A (es) | 2018-11-30 | 2021-09-10 | Juno Therapeutics Inc | Metodos de dosificacion y tratamiento de canceres de celulas b en terapia celular adoptiva. |
| BR112021020447A2 (pt) | 2019-04-17 | 2022-05-17 | Alpine Immune Sciences Inc | Métodos e usos de proteínas de fusão de ligante icos variante (icosl) |
| AU2020287882A1 (en) | 2019-06-07 | 2022-01-20 | Juno Therapeutics, Inc. | Automated T cell culture |
| CN114269371A (zh) | 2019-06-12 | 2022-04-01 | 朱诺治疗学股份有限公司 | 细胞介导的细胞毒性疗法与促存活bcl2家族蛋白的抑制剂的组合疗法 |
| CN114555112A (zh) | 2019-08-22 | 2022-05-27 | 朱诺治疗学股份有限公司 | T细胞疗法和zeste增强子同源物2(ezh2)抑制剂的组合疗法及相关方法 |
| JP2022554348A (ja) | 2019-11-05 | 2022-12-28 | ジュノー セラピューティクス インコーポレイテッド | 治療用ｔ細胞組成物の属性を決定する方法 |
| CN115398231A (zh) | 2019-12-06 | 2022-11-25 | 朱诺治疗学股份有限公司 | 与治疗b细胞恶性肿瘤的细胞疗法相关的毒性和反应的相关方法 |
| EP4093433A1 (en) | 2020-01-24 | 2022-11-30 | Juno Therapeutics, Inc. | Methods for dosing and treatment of follicular lymphoma and marginal zone lymphoma in adoptive cell therapy |
| EP4097218A1 (en) | 2020-01-28 | 2022-12-07 | Juno Therapeutics, Inc. | Methods for t cell transduction |
| WO2021207689A2 (en) | 2020-04-10 | 2021-10-14 | Juno Therapeutics, Inc. | Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen |
| US12202882B2 (en) | 2020-05-08 | 2025-01-21 | Alpine Immune Sciences, Inc. | APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof |
| EP4150640A1 (en) | 2020-05-13 | 2023-03-22 | Juno Therapeutics, Inc. | Methods of identifying features associated with clinical response and uses thereof |
| HUE071824T2 (hu) | 2020-10-15 | 2025-09-28 | Hoffmann La Roche | Nukleinsav-konstruktumok VA RNS transzkripcióhoz |
| WO2022133030A1 (en) | 2020-12-16 | 2022-06-23 | Juno Therapeutics, Inc. | Combination therapy of a cell therapy and a bcl2 inhibitor |
| KR20230159851A (ko) | 2021-03-22 | 2023-11-22 | 주노 쎄러퓨티크스 인코퍼레이티드 | 치료 세포 조성물의 효력을 결정하는 방법 |
| AU2022244229A1 (en) | 2021-03-22 | 2023-09-14 | Juno Therapeutics, Inc. | Method to assess potency of viral vector particles |
| AU2022246593A1 (en) | 2021-03-29 | 2023-10-12 | Juno Therapeutics, Inc. | Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy |
| CA3216795A1 (en) | 2021-05-07 | 2022-11-10 | Alpine Immune Sciences, Inc. | Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein |
| US20250059560A1 (en) | 2021-12-16 | 2025-02-20 | Sana Biotechnology, Inc. | Methods and systems of particle production |
| US20250101379A1 (en) | 2022-01-28 | 2025-03-27 | Juno Therapeutics, Inc. | Methods of manufacturing cellular compositions |
| WO2023172883A1 (en) | 2022-03-07 | 2023-09-14 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses |
| WO2023230548A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Method for predicting response to a t cell therapy |
| EP4543923A1 (en) | 2022-06-22 | 2025-04-30 | Juno Therapeutics, Inc. | Treatment methods for second line therapy of cd19-targeted car t cells |
| AU2023356958A1 (en) | 2022-10-04 | 2025-04-03 | Alpine Immune Sciences, Inc. | Mutated taci-fc fusion proteins for use in the treatment of autoantibody-mediated diseases |
| WO2024220588A1 (en) | 2023-04-18 | 2024-10-24 | Juno Therapeutics, Inc. | Cytotoxicity assay for assessing potency of therapeutic cell compositions |
| WO2024226858A1 (en) | 2023-04-26 | 2024-10-31 | Juno Therapeutics, Inc. | Methods for viral vector manufacturing |
| WO2024243365A2 (en) | 2023-05-23 | 2024-11-28 | Juno Therapeutics, Inc. | Activation markers of t cells and method for assessing t cell activation |
| WO2024263991A2 (en) * | 2023-06-22 | 2024-12-26 | Arc Research Institute | Methods and compositions for integration deficient viral vectors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5861161A (en) | 1994-09-07 | 1999-01-19 | Universite De Montreal | Chimeric proteins comprising a Vpr/Vpx virion incorporation domain for targeting into HIV-1 or HIV-2 virions |
| CN1940076A (zh) * | 1995-11-28 | 2007-04-04 | 约翰斯.霍普金斯大学医学院 | 条件复制型病毒载体及其用法 |
| AU1100201A (en) | 1999-10-28 | 2001-05-08 | Board Of Trustees Of The Leland Stanford Junior University | Methods of in vivo gene transfer using a sleeping beauty transposon system |
| US6673567B2 (en) | 2000-03-23 | 2004-01-06 | E. I. Du Pont De Nemours And Company | Method of determination of gene function |
| US20030003565A1 (en) * | 2000-11-27 | 2003-01-02 | Dubensky Thomas W. | Functional lentiviral vector from an MLV-based backbone |
| WO2004022761A1 (en) | 2002-09-03 | 2004-03-18 | Oxford Biomedica (Uk) Limited | Retroviral vector and stable packaging cell lines |
| US7220578B2 (en) * | 2002-11-27 | 2007-05-22 | Tal Kafri | Single LTR lentivirus vector |
| EP2055316A1 (en) * | 2003-09-09 | 2009-05-06 | VIRxSYS Corporation | Lentivirus vector-based approaches for generating an immune response to HIV in humans |
| GB0325379D0 (en) | 2003-10-30 | 2003-12-03 | Oxford Biomedica Ltd | Vectors |
| EP1706153A1 (en) * | 2003-12-04 | 2006-10-04 | Childrens Hospital of Los Angeles Research Institute | Minimal lentiviral vector system |
| US20070048285A1 (en) * | 2005-08-24 | 2007-03-01 | Christopher Baum | Self-inactivating retroviral vector |
| EP1757703A3 (en) | 2005-08-24 | 2007-12-05 | Medizinische Hochschule Hannover | Self-inactivating retroviral vector |
| WO2009076524A2 (en) | 2007-12-11 | 2009-06-18 | The University Of North Carolina At Chapel Hill | Polypurine tract modified retroviral vectors |
-
2008
- 2008-12-11 WO PCT/US2008/086409 patent/WO2009076524A2/en not_active Ceased
- 2008-12-11 NO NO08859393A patent/NO2222861T3/no unknown
- 2008-12-11 RS RS20180107A patent/RS56844B1/sr unknown
- 2008-12-11 PT PT88593934T patent/PT2222861T/pt unknown
- 2008-12-11 SI SI200831929T patent/SI2222861T1/en unknown
- 2008-12-11 EP EP08859393.4A patent/EP2222861B1/en active Active
- 2008-12-11 PL PL08859393T patent/PL2222861T3/pl unknown
- 2008-12-11 DK DK08859393.4T patent/DK2222861T3/en active
- 2008-12-11 ES ES08859393.4T patent/ES2664988T3/es active Active
- 2008-12-11 JP JP2010538155A patent/JP5749014B2/ja not_active Expired - Fee Related
- 2008-12-11 LT LTEP08859393.4T patent/LT2222861T/lt unknown
- 2008-12-11 US US12/747,076 patent/US9796987B2/en active Active
- 2008-12-11 EP EP17204678.1A patent/EP3342872A1/en not_active Withdrawn
- 2008-12-11 TR TR2018/02323T patent/TR201802323T4/tr unknown
- 2008-12-11 HU HUE08859393A patent/HUE036103T2/hu unknown
- 2008-12-11 HR HRP20180184TT patent/HRP20180184T1/hr unknown
-
2015
- 2015-01-28 JP JP2015013974A patent/JP6001702B2/ja not_active Expired - Fee Related
-
2017
- 2017-10-23 US US15/790,530 patent/US10017785B2/en active Active
-
2018
- 2018-02-09 CY CY20181100167T patent/CY1119905T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2664988T3 (es) | 2018-04-24 |
| SI2222861T1 (en) | 2018-04-30 |
| PL2222861T3 (pl) | 2018-04-30 |
| PT2222861T (pt) | 2018-02-16 |
| NO2222861T3 (cg-RX-API-DMAC7.html) | 2018-05-05 |
| LT2222861T (lt) | 2018-03-26 |
| TR201802323T4 (tr) | 2018-03-21 |
| EP2222861B1 (en) | 2017-12-06 |
| DK2222861T3 (en) | 2018-02-05 |
| US20180119170A1 (en) | 2018-05-03 |
| WO2009076524A2 (en) | 2009-06-18 |
| JP5749014B2 (ja) | 2015-07-15 |
| HRP20180184T1 (hr) | 2018-04-06 |
| JP6001702B2 (ja) | 2016-10-05 |
| US10017785B2 (en) | 2018-07-10 |
| WO2009076524A3 (en) | 2009-09-11 |
| EP2222861A2 (en) | 2010-09-01 |
| CY1119905T1 (el) | 2018-06-27 |
| EP2222861A4 (en) | 2011-12-28 |
| EP3342872A1 (en) | 2018-07-04 |
| JP2011505835A (ja) | 2011-03-03 |
| RS56844B1 (sr) | 2018-04-30 |
| JP2015119715A (ja) | 2015-07-02 |
| US9796987B2 (en) | 2017-10-24 |
| US20100323403A1 (en) | 2010-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT2222861T (lt) | Retrovirusiniai vektoriai modifikuoti polipurino atkarpa | |
| GB0714384D0 (en) | theraputic agents | |
| GB0717839D0 (en) | The treepee | |
| GB201004087D0 (en) | Fullerene dervative | |
| GB0706914D0 (en) | Novel adenovirus vectors | |
| EP2182833A4 (en) | ENDOSCOPE | |
| GB2445808B (en) | Buckle | |
| GB0702228D0 (en) | The cosy-cushion | |
| GB0718192D0 (en) | Mooring aid | |
| GB0707146D0 (en) | The bealyboard | |
| GB0702694D0 (en) | Vectors | |
| GB0711387D0 (en) | The fincubator | |
| GB0701309D0 (en) | The easi-strutt | |
| TWI366664B (en) | Compass | |
| GB0709255D0 (en) | Wound diagnosis | |
| HU0700013D0 (en) | Combined flipper | |
| GB0719757D0 (en) | Assay | |
| GB0722912D0 (en) | Assay | |
| GB0715725D0 (en) | Assay | |
| GB0715386D0 (en) | Assay | |
| GB0711955D0 (en) | Assay | |
| GB0721944D0 (en) | Assay | |
| GB0721228D0 (en) | Manger | |
| IL183094A0 (en) | Sailboat | |
| GB0723137D0 (en) | Electrochemical assay |